Janux Therapeutics financials
$16.95+2.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3M | $3.7M | $0.00 | $10.0M | $0.00 | $0.00 | $0.00 | $439.0K | $8.9M | $1.3M | $2.5M | $2.5M |
| Gross profit | $10.3M | $3.7M | $0.00 | $10.0M | $0.00 | $0.00 | $0.00 | $439.0K | $8.9M | $1.3M | $2.5M | $2.5M |
| Gross margin | 100.0% | 100.0% | — | 100.0% | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$31.7M | -$34.2M | -$42.4M | -$35.3M | -$45.1M | -$34.9M | -$29.0M | -$35.8M | -$13.8M | -$20.2M | -$16.1M | -$15.8M |
| Net income | -$22.0M | -$24.4M | -$31.9M | -$24.3M | -$33.9M | -$23.5M | -$20.2M | -$28.1M | -$6.0M | -$14.8M | -$11.8M | -$11.6M |
| Net margin | −214.0% | −652.6% | — | −243.1% | — | — | — | −6391.6% | −67.0% | −1178.9% | −477.8% | −459.6% |
| Diluted EPS | $-0.35 | $-0.39 | $-0.51 | $-0.39 | $-0.55 | $-0.38 | $-0.36 | $-0.51 | $-0.11 | $-0.30 | $-0.25 | $-0.25 |
| EBITDA | -$31.2M | -$33.7M | -$41.9M | -$34.8M | -$44.6M | -$34.4M | -$28.5M | -$35.3M | -$13.3M | -$19.6M | -$16.1M | -$15.3M |
| Operating cash flow | $12.5M | -$12.3M | -$28.5M | -$12.9M | -$23.8M | -$17.0M | -$16.7M | -$2.2M | -$10.0M | -$14.8M | -$9.9M | -$11.7M |
| Free cash flow | $12.3M | -$12.6M | -$28.6M | -$12.9M | -$24.3M | -$17.4M | -$16.8M | -$2.3M | -$10.1M | -$15.0M | -$10.4M | -$12.2M |
| Diluted shares | 62.9M | 62.7M | 62.2M | 62.0M | 61.9M | 61.8M | 56.9M | 54.6M | 54.5M | 49.0M | 46.8M | 45.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.8M | $51.8M | $52.3M | $48.4M | $52.4M | $73.7M |
| Short-term investments | $943.1M | $904.6M | $914.2M | $940.6M | $943.6M | $940.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.01B | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B |
| Total liabilities | $79.7M | $86.7M | $44.7M | $48.2M | $41.7M | $38.3M |
| Shareholders' equity | $928.0M | $941.5M | $956.8M | $976.6M | $990.5M | $1.01B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology